Objective-To investigate the effects of pioglitazone (PIO), a peroxisome proliferator-activated receptor ␥ agonist, on plaque matrix metalloproteinase (MMP) and macrophage (Mac) responses in vivo in a molecular imaging study. Methods and Results-In vitro, PIO suppressed MMP-9 protein expression in murine peritoneal Macs (PϽ0.05). To assess PIO's effects on plaque inflammation, nondiabetic apolipoprotein E Ϫ/Ϫ mice receiving a high-cholesterol diet (HCD) were administered an MMP-activatable fluorescence imaging agent and a spectrally distinct Mac-avid fluorescent nanoparticle. After 24 hours, mice underwent survival dual-target intravital fluorescence microscopy of carotid arterial plaques. These mice were then randomized to HCD or HCD plus 0.012% PIO for 8 weeks, followed by a second intravital fluorescence microscopy study of the same carotid plaque. In the HCD group, in vivo MMP and Mac target-to-background ratios increased similarly (PϽ0.01 versus baseline). In contrast, PIO reduced MMP and Mac target-to-background ratios (PϽ0.01) versus HCD. Changes in MMP and Mac signals correlated strongly (r Ն0.75). Microscopy demonstrated MMP and Mac reductions in PIO-treated mice and a PIO-modulated increase in plaque collagen. Conclusion-Serial optical molecular imaging demonstrates that plaque MMP and Mac activity in vivo intensify with hypercholesterolemia and are reduced by PIO therapy. (Arterioscler Thromb Vasc Biol.
I nflammation is involved in all stages of atherosclerosis, including foam cell formation, plaque progression, and ultimately plaque disruption and thrombus formation. 1 Systemic inflammation correlates with an increased rate of fatal cardiovascular disease events, 2,3 even in statin-treated patients achieving target serum cholesterol levels. 4 Accordingly, pharmacological strategies to reduce key inflammatory targets, such as plaque macrophages (Macs) and plaque proteases, appear promising for reducing cardiovascular disease events. 5 Although in use as an antidiabetic agent, the thiazolidinedione (TZD) pioglitazone (PIO), a peroxisome proliferator-activated receptor (PPAR) ␥ agonist, is also an intriguing inflammatory-modulating agent that may reduce cardiovascular death, myocardial infarction, and stroke. 6, 7 PPAR-␥ is a ligand-activated nuclear receptor/transcription factor that regulates adipogenesis, insulin sensitivity, and lipid metabolism. In addition, PPAR-␥ agonists exert diverse anti-inflammatory actions important in atherosclerosis, including (1) reducing destabilizing matrix metalloproteinases (MMPs) in Macs, vascular smooth muscle cells, and endothelial cells; and (2) reducing the recruitment of T cells and monocytes/Macs, key effector cells in atherosclerosis. 8 -10 Despite ex vivo evidence linking PIO to reduced atheroma inflammation, the anti-inflammatory effects of PIO on plaque MMP activity and Macs have not been spatially mapped, tracked, and quantified in vivo. In addition, questions exist regarding potential clinical differences among the TZDs in terms of cardiovascular effects, suggesting that in vivo approaches may be needed to resolve such issues. Furthermore, although PPAR-␥ agonists, such as PIO, decrease destabilizing MMP expression in the atheromata, it is unknown whether this reflects primarily (1) reduced MMP expression from a stable number of plaque Macs or (2) reduced numbers of Macs, the cells responsible for most of the MMP expression in the atheromata. 11 To address these open questions, we harnessed serial dual-target fluorescence molecular imaging to (1) perform longitudinal spatial assessment of PIO-and hypercholesterolemic-modulated alterations of plaque inflammation and (2) investigate whether changes in plaque MMP activity track with changes in plaque Mac activity, as assessed by in vivo imaging and ex vivo molecular analyses. By using this novel strategy, our findings provide unequivocal in vivo evidence that PIO reduces plaque inflammation and that decreases in plaque MMP activity correlate strongly with reductions in plaque Mac phagocytic activity.
Methods
In vitro studies (Western blotting), fluorescence microscopy, image analysis, histopathological features, plasma measurements, and MMP and Mac molecular imaging agents are detailed in the supplemental data (available online at http://atvb.ahajournals.org).
Serial Dual-Target Fluorescence Molecular Imaging of Plaque Inflammation
PIO's effects on carotid plaques were investigated in apolipoprotein E (apoE) Ϫ/Ϫ mice (nϭ16 female mice; Jackson Laboratories, Bar Harbor, Me). Mice consumed a high-cholesterol diet (HCD; TD88137; 42% milk fat and 0.2% cholesterol; Harlan Teklad, Madison, Wis) from the age of 10 to 26 weeks. Twenty-four hours before imaging, MMP and Mac agents were coinjected (tail vein). Next, apoE Ϫ/Ϫ mice underwent intravital fluorescence microscopy (IVFM 1) after surgical exposure of the right carotid artery. 12 Briefly, the distal right common carotid artery was carefully separated from the periadventitial tissues by blunt dissection. For coregistration, a phantom was placed underneath the carotid artery bifurcation. After the initial IVFM study, the incisions of the 16 apoE Ϫ/Ϫ mice were surgically closed. Mice recovered from surgery without incident and were allowed water and their specified diet ad libitum. An additional group of wild-type C57BL/6J mice fed a normal chow diet (nϭ6) were injected with MMP and Mac imaging agents; these mice served as controls.
ApoE Ϫ/Ϫ mice with carotid atheromata detected on the first IVFM study (IVFM 1) were then randomized to either continued HCD or HCD supplemented with PIO, 0.012% wt/wt, ad libitum, for 8 weeks. After 8 weeks (when the mice were aged 34 weeks), apoE Ϫ/Ϫ mice were reinjected with the same dosages of MMP and Mac imaging agents. Twenty-four hours later, the same carotid atheroma was visualized in IVFM 1 and the mice underwent a second IVFM (IVFM 2) before euthanasia and histopathological analyses. The Subcommittee on Research Animal Care at Massachusetts General Hospital, Boston, approved all procedures.
Intravital Fluorescence Microscopy
IVFM studies used a multichannel laser scanning fluorescence microscope (supplemental data). The ϫ4 objective (numerical aperture, 0.15) used provided an in-plane resolution of 13ϫ13 m. A plastic tube phantom (PE-10 tubing; Becton Dickinson, Franklin Lakes, NJ) was placed underneath the carotid artery bifurcation and served to coregister the imaging fields of the 2 IVFM data sets. The plaque target-to-background ratio (TBR) was calculated as the ratio of plaque signal intensity to the adjacent vessel background signal intensity (supplemental data).
Results

PIO Represses Cytokine-Induced MMP-9 Expression In Vitro
To determine whether PPAR-␥ activation by PIO represses MMP-9 protein expression in vitro, isolated mouse peritoneal Macs were plated and cultured in the presence of lipopolysaccharide and/or PIO, 10 mol/L. PIO pretreatment attenuated the lipopolysaccharide-augmented protein expression of MMP-9, as seen on immunoblotting: (data expressed as meanϮSEM) control, 34 
Effect of PIO Therapy on Body Weight and Metabolic Parameters
PIO-treated apoE Ϫ/Ϫ mice, 13 mg/kg per day, showed reduced plasma cholesterol levels and a similar body weight and plasma glucose, insulin, and triglyceride levels as HCD-treated mice (supplemental Table) , consistent with a prior study. 13
Dual-Target Fluorescence Molecular Imaging of Carotid Atherosclerosis Reveals Abundant In Vivo MMP Activity and Mac Signals Compared With Healthy Vessels
Survival IVFM in cholesterol-fed 26-week-old apoE Ϫ/Ϫ mice (nϭ16) was performed to assess in vivo carotid plaque inflammation at baseline. Twenty-four hours before imaging, dual-targeted and spectrally resolved MMP activity (MMPSense680) and Mac phagocytic activity (cross-linked iron oxide [CLIO]-cyanine 7 [Cy7]) near infrared fluorescence (NIRF) imaging agents were coinjected. At the beginning of the imaging session, a third spectrally distinct intravascular agent (fluorescein isothiocyante-dextran) was administered and multichannel high-resolution IVFM was performed.
Plaques were located in the distal common carotid artery and its bifurcation. Discrete MMP (green) and Mac (red) plaque NIRF signals were confirmed to be intravascular by fluorescein isothiocyante-dextran (blue)-based carotid arterial angiograms. The angiogram provided precise identification of the plaque boundaries to enable accurate region of interest analyses of the molecular imaging targets of MMP and Mac activity ( Figure 1 ). The carotid arteries of control C57BL/6J mice injected with the same agents showed mild near infrared (NIR) fluorescence diffusely throughout the vessel wall; no plaques were evident, as expected. Z stacks demonstrated significantly more MMP and Mac signals in apoE Ϫ/Ϫ mice compared with C57BL/6J mice: MMP TBR, 1.9Ϯ0.1 versus 1.2Ϯ0.1 (PϽ0.001); and Mac TBR, 2.4Ϯ0.1 versus 1.1Ϯ0.1 (PϽ0.001).
PIO Suppresses Plaque MMP Activity and Macs In Vivo
To assess the in vivo inflammation-modulating effects of hypercholesterolemia and PIO therapy, a second follow-up IVFM study was performed to measure changes in carotid plaque MMP and Mac activity over time. At the age of 26 weeks, 13 (81%) of the 16 apoE Ϫ/Ϫ mice had carotid arterial plaques on baseline IVFM imaging, and were randomized to either continued HCD (group 1, HCD; nϭ6) or HCD admixed with PIO (group 2, HCD plus PIO; nϭ7). The baseline MMP and Mac plaque activities were similar between these 2 groups (baseline MMP TBR of group 1 versus group 2, 1.8Ϯ0. 1 Figure 3E ).
The natural history of in vivo plaque MMP and Mac activity during the 8-week study period differed significantly between 
Plaque MMP Activity Exhibits a Linear Relationship With Plaque Macs
To better understand the relationship between plaque MMP activity and plaque Mac activity in vivo, Pearson correlation coefficients between the ⌬MMP TBR and ⌬Mac TBR were derived (Figure 4 ). In the entire cohort, a strong relationship existed between the ⌬MMP TBR and ⌬Mac TBR (rϭ0.96, PϽ0.001). Subgroup analyses revealed a stronger correlation in the PIO-modulated group (rϭ0.92, Pϭ0.003) compared with the HCD group (rϭ0.75, Pϭ0.08).
PIO Reduces Corresponding Histological, Microscopic, and Molecular Measures of Plaque Inflammation
Compared with carotid atherosclerotic plaques of HCD-fed apoE Ϫ/Ϫ mice, plaques of PIO-treated HCD-fed apoE Ϫ/Ϫ mice contained reduced MMP-9 and Mac presence: percentage MMP-9 staining for HCD versus HCD plus PIO, 42.6Ϯ4.0% versus 14.3Ϯ2.8% (66% reduction) (PϽ0.001); and percentage Mac staining for HCD versus HCD plus PIO, 38.3Ϯ4.2% versus 14.1Ϯ2.4% (63% reduction) (PϽ0.001) ( Figure 5 ). On multichannel fluorescence microscopy, carotid plaque sections revealed colocalization of MMP activity and Mac molecular imaging signals. In contrast to animals fed an HCD, PIO-treated animals had substantially reduced plaque MMP activity and Mac signals. Similar levels of NIR autofluorescence emanated from the medial fibers of plaques from both groups.
Next, immunoblots of MMP-9 and Mac expression were examined to evaluate whether PIO reduced aortic vessel wall MMP-9 and Mac-specific protein levels. Consistent with the IVFM, histological, and fluorescence microscopy studies, PIO reduced aortic MMP-9 and Mac-3 protein levels in apoE Ϫ/Ϫ mice (63% and 67% reductions: Pϭ0.01 and Pϭ0.005, respectively) ( Figure 6 ).
PIO Increases Plaque Collagen Content Without Altering Lesion Size
Given the reduced plaque inflammatory composition after PIO therapy, we investigated whether PIO might induce a compensatory increase in plaque collagen content. In fact, the Masson trichrome stain for collagen demonstrated increased carotid and aortic plaque collagen in the PIO group, with a 72% increase in the aortic intimal lesion collagen content (percentage collagen area for HCD versus HCD plus PIO, 17.3Ϯ2.6% versus 29.7Ϯ3.2%; Pϭ0.01) ( Figure 5E and supplemental Figure II ). Similar levels of collagen staining in the media were noted. No reduction in aortic plaque area was found (HCD versus HCD plus PIO, 0.42Ϯ0.03 mm 2 versus 0.45Ϯ0.02 mm 2 ; Pϭ0.45).
Discussion
By using serial dual-targeted fluorescence molecular imaging coupled to ex vivo molecular methods, this study provides novel in vivo evidence that PIO reduces inflammation in atherosclerosis. Plaque MMP and Mac activity progressively increased in vivo in hypercholesterolemic apoEϪ/Ϫ mice and was reduced by the TZD PPAR-␥ agonist PIO. Furthermore, this study provides additional insight into the temporal relationship of MMP and Mac activities in atherosclerosis. Specifically, we found that alterations in plaque MMPs were strongly linked to alterations in plaque Macs, as assessed by in vivo activity imaging, fluorescence microscopy, immunohistochemistry, and immunoblotting.
MMPs, zinc-dependent endopeptidases that digest collagen, elastin, and extracellular proteins, are implicated in plaque destabilization by promoting both expansive remodeling and fibrous cap rupture. 11 In this study, in vivo functional MMP activity, rather than the sole presence of MMPs, was imaged using an MMP-activatable NIRF substrate, 14, 15 in concert with optimized IVFM. 12 Serial IVFM demonstrated that carotid plaque MMP activity increased by 42% in the HCD group (Figures 2 and 3) . In contrast, PIO treatment reduced in vivo plaque MMP activity by 13% (PϽ0.05 versus the HCD control group), extending a prior ex vivo PIO study 16 into the in vivo realm. MMP-9 was directly investigated for 3 reasons: (1) MMP-9 is a well-established destabilizing factor in atherogenesis, promoting both expansive remodeling and fibrous cap disruption 11 ; (2) prior stud- ies 17, 18 suggest that TZDs may downregulate MMP-9 expression in cellular models, including Macs; and (3) MMP-9 substantially activates the MMP imaging agent (MMPSense) in atherosclerosis. 15 Recent MMP9 gene deletion studies further support MMP-9 as a dominant activator of the NIRF imaging agent. 19 Corroborating the in vivo molecular imaging findings, we found that PIO reduced MMP-9 expression by 66% and 63% on respective immunohistochemical and immunoblotting studies of atherosclerotic tissues (Figures 5 and 6) .
The observed reductions in plaque MMP activity in vivo could be because of the combination of the following factors: (1) suppression of MMP expression from resident Macs, as demonstrated in vitro for various PPAR-␥ agonists 17, 18 and herein specifically for the TZD PIO (supplemental Figure I) ;
(2) reductions in present or recruited plaque Macs; (3) changes in MMP inhibitor levels independent of any regulation of MMP mRNA expression or protein levels; and/or (4) a change in other non-Mac cells exerting a paracrine effect. To elucidate the relative contributions of these possibilities, we simultaneously imaged Mac phagocytic activity using spectrally distinct dextran-coated fluorescent nanoparticles validated for detecting plaque Macs. 20 These unmodified nanoparticles are similarly absorbed by resting and activated Macs in vitro 21 and do not target apoptotic cells. 22 In the HCD group, we observed a 43% TBR increase in plaque Mac activity (Figures 2 and 3) , similar to the 42% TBR increase in plaque MMP activity. In the PIO group, PIO reduced Mac activity by 19%, similar to the observed 13% reduction in MMP activity. Concurrent fluorescence microscopy, immunohistochemical, and immunoblotting analyses confirmed that PIO reduced plaque Mac content, as previously noted ex vivo. 16 Notably, PIO-mediated reductions in plaque MMP activity were highly similar to reductions in plaque Macs by all in vivo and ex vivo measures.
To further assess the relationship between in vivo plaque MMP and Mac activity, we derived Pearson correlation coefficients (Figure 4) . A significant relationship existed between the ⌬MMP TBR and the ⌬Mac TBR (rϭ0.96), with a stronger correlation evident in the PIO subgroup (rϭ0.92) compared with the HCD subgroup (rϭ0.75). The ability to assess and correlate these concomitant changes in plaque inflammation stemmed from the serial 2-point imaging method of the same carotid plaque for a given subject.
The integrated in vivo molecular imaging, microscopic, histological, and protein immunoblotting results suggest that PIO-mediated reductions in plaque MMP activity and presence are predominantly because of the reduced number of Macs that furnish MMPs, rather than reduced MMP expression from a numerically static Mac population. TZD-relevant mechanisms that may underlie reductions in plaque Macs, while beyond the scope of this investigation, include the following: (1) reduced monocyte recruitment via decreased expression of leukocyte adhesion molecules 23, 24 and/or decreased monocyte chemotaxis 25, 26 ; and (2) increased TZDmediated apoptosis of Macs. 13, 27 From a translational imaging agent perspective, both Macs and MMP activity are viable clinical atherosclerosis molecular imaging targets. 28 -31 Iron oxide magnetic nanoparticles are already clinically used in noninvasive pharmacological MRI studies of Mac responses in the atherosclerotic plaques of carotid arteries. 32 In addition, the backbone of the MMP-activatable agent has been safely tested in clinical trials, and a related cysteine protease-activatable NIRF agent is planned for clinical trials. 31 From a clinical technology perspective, NIR fluorescence molecular imaging is positioned well to interrogate the human coronary arteries via clinically translatable intravascular catheters that detect NIRF plaque inflammation through blood in coronary-sized arteries. 33 From a noninvasive perspective, fluorescence molecular tomographic-based systems (3D noninvasive imaging systems that reconstruct fluorescence quantitatively deep in tissue) 34 can be scaled up for interrogating the human carotid arteries, with and without ultrasonographic integration. Advances in either of these 2 arenas, coupled with Food and Drug Administration approval of appropriate NIRF imaging agents, may enable a clinical investigation of the antiinflammatory effects of PIO in atherosclerosis.
Additional study findings merit further discussion regarding PIO's effects on atherosclerosis. In contrast to a prior key atherosclerosis investigation of PPAR-␥ agonists by Li et al, 35 showing nonsignificant reductions in inflammatory plaque markers in female mice, this investigation found significant reductions in plaque MMP-9 and Mac levels. Potential explanations for this difference might include the use of rosiglitazone in the prior study as opposed to PIO and the prior use of low-density lipoprotein receptor-deficient mice rather than apoE Ϫ/Ϫ mice. PIO also reduced low-density lipoprotein levels, as noted by other researchers, 13 which may also have contributed to the changes seen. Further mechanistic studies are needed to distinguish the relative contributions of PPAR activation and cholesterol alterations in the reductions of plaque inflammation observed herein. In addition, although not the focus of this in vivo inflammation investigation, PIO administered at a 3 times higher dose (ie, 40 mg/kg per day) has been reported to promote necrotic core formation 13 but was not found at the lower dose used herein. 36 The histological analysis of the carotid artery, a vessel much less investigated in murine atherosclerosis studies, as opposed to the aortic root or the inominate artery, was also important. Immunohistochemical analyses of carotid plaque MMP-9 and Macs were supplemented with more established plaque measurements, including whole aorta immunoblots, which also demonstrated reduced MMP-9 and Mac content and plaque area. The collagen content also increased, as seen by others. 16 Last, experimental murine PIO dosages are higher than human dosages (Ͻ1 mg/kg per day); therefore dedicated clinical studies will be necessary to assess whether PIO can reduce human plaque inflammation.
Ultimately, additional clinical outcome trials in both nondiabetic and diabetic human subjects are needed to determine the net clinical and dose-dependent effect of PIO and distinctions between different PPAR-␥ agonists. More specific in vivo assessments are required given the complexity of both the atherosclerotic disease process and transcriptional modifiers, such as PPAR agonists, which have complex effects and both stabilizing and destabilizing actions. Integrated biological and imaging studies in vivo in both mice and humans hold the potential to provide more specific and detailed information regarding antiatherosclerotic strategies.
